Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)

G. Palmieri, G. Merola, P. Federico, L. Petillo, M. Marino, M. Lalle, M. Milella, A. Ceribelli, L. Montella, C. Merola, S. del Prete, M. Bergaglio, S. de Placido, G. di Lorenzo

Research output: Contribution to journalArticlepeer-review

Abstract

Background: No previous prospective trials have been reported with capecitabine and gemcitabine (CAP-GEM) in patients with metastatic thymic epithelial tumors (TETs). We conducted a multicenter study to determine the activity and tolerability of this regimen in pretreated TETs. Patients and methods: A total of 15 patients were enrolled in the first stage of phase II study. All patients received CAP-GEM every 3 weeks. The primary end point was objective response rate (RR); secondary end points were toxicity, progression-free survival (PFS) and overall survival. Results: Complete responses (CR) and partial responses were observed in three (20%) and three (20%) patients for a 40% RR, respectively. Grade 1-2 neutropenia, anemia and thrombocytopenia were the most common side-effects, noted in seven (46.7%), five (33.3%) and five (33.3%) patients, respectively. The most common grade 3 toxicity was neutropenia in three patients (20%). Median PFS was 11 months (95% confidence interval 4-17). The 1-and 2-year survival rates were 80% and 67%, respectively. Conclusion: We have decided to publish the preliminary results because this regimen was more active than that expected. Although our results are preliminary, CAP-GEM shows activity and safety in pretreated TETs. Furthermore, multicenter trials, also in first-line setting, are necessary to confirm our results.

Original languageEnglish
Pages (from-to)1168-1172
Number of pages5
JournalAnnals of Oncology
Volume21
Issue number6
DOIs
Publication statusPublished - Oct 30 2009

Keywords

  • Capecitabine
  • Gemcitabine
  • Pretreated patients
  • Thymic epithelial tumor

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)'. Together they form a unique fingerprint.

Cite this